natgillin/translations-raw huggingface dataset:
The primary endpoints of this study, progression-free survival (PFS), as assessed by hazard ratio, and overall response rate (ORR) were determined based on assessments made by a blinded Independent Review Committee (IRC). 
Primarne mjere ishoda u ovom ispitivanju - preživljenje bez progresije bolesti (engl. progression-free survival, PFS) ocijenjeno prema omjeru hazarda te stopa ukupnog odgovora (engl. overall response rate, ORR) - određivale su se na temelju ocjena zaslijepljenog Neovisnog ocjenjivačkog povjerenstva
As an IgG monoclonal antibody, elotuzumab is expected to be degraded into small peptides and amino acids via catabolic pathways. 
Budući da je elotuzumab IgG monoklonsko protutijelo, očekuje se da će se kataboličkim putovima razgraditi na male peptide i aminokiseline.
Upper respiratory tract infection 
Infekcija gornjih dišnih putova
SLAMF7 is also expressed on natural killer cells (NK), normal plasma cells, and other immune cells including some T cell subsets, monocytes, B cells, macrophages, and pDCs (plasmacytoid dendritic cells), but is not detected on normal solid tissues or haematopoietic stem cells. 
SLAMF7 se također eksprimira i na prirodnoubilačkim (engl. natural killer, NK) stanicama, normalnim plazmatskim stanicama te drugim stanicama imunološkog sustava, uključujući neke podskupine T-stanica, monocite, B-stanice, makrofage i plazmacitoidne dendritične stanice (engl. plasmacytoid dendritic cell, pDC), ali nije prisutan na normalnim solidnim tkivima ni hematopoetskim matičnim stanicama.
Before each infusion of Empliciti, you will be given medicines to reduce infusion reaction (see section 3 “How to use Empliciti, Medicines given before each infusion”). 
Prije svake infuzije lijeka Empliciti dobit ćete lijekove kako bi se ublažila reakcija na infuziju (pogledajte odlomak "Lijekovi koje ćete primiti prije svake infuzije" u dijelu 3.
The entire Empliciti infusion should be administered with an infusion set and a sterile, non-pyrogenic, low-protein-binding filter (with a pore size of 0.2-1.2 µm) using an automated infusion pump. 
Cijelu infuziju lijeka Empliciti treba primijeniti infuzijskim setom i sterilnim, nepirogenim filtrom male sposobnosti vezanja proteina (veličina pora: 0,2 - 1,2 μm) uz pomoć automatizirane infuzijske pumpe.
Infusion reactions Empliciti has been associated with infusion reactions (see section 2 “Warnings and precautions”). 
Empliciti se povezuje s reakcijama na infuziju (pogledajte odlomak "Upozorenja i mjere opreza" u dijelu 2.).
Empliciti is used to treat multiple myeloma (a cancer of the bone marrow) in adults. 
Empliciti se koristi za liječenje multiplog mijeloma (raka koštane srži) u odraslih osoba.
Median OS was not reached for E-Pd treatment group. 
Nije dosegnut medijan OS-a u skupini koja je primala E-Pd.
Lenalidomide 25 mg was taken orally once daily for the first 3 weeks of each cycle. 
Lenalidomid se primjenjivao u peroralnoj dozi od 25 mg jedanput na dan tijekom prva 3 tjedna svakog ciklusa.
Prior to Empliciti infusion, dexamethasone was administered as a divided dose: an oral dose of 28 mg and an intravenous dose of 8 mg. 
Prije infuzije lijeka Empliciti, deksametazon se primjenjivao podijeljen u dvije doze: peroralnu dozu od 28 mg i intravensku dozu od 8 mg.
Grade 3/4 
Učestalost 3./4. stupnja
Premedication for prevention of infusion reaction Patients must be administered with the following premedications 45-90 minutes prior to Empliciti infusion (see section 4.4): Dexamethasone 8 mg intravenous H1 blocker: diphenhydramine (25-50 mg orally or intravenous) or equivalent H1 blocker. 
Premedikacija u svrhu prevencije reakcija na infuziju Bolesnicima se 45 - 90 minuta prije infuzije lijeka Empliciti mora primijeniti sljedeća premedikacija (vidjeti dio 4.4): Deksametazon 8 mg intravenski Blokator H1 receptora: difenhidramin (25 - 50 mg peroralno ili intravenski) ili ekvivalentni blokator H1 receptora.
Very severe infusion reactions (≥ Grade 3) may require permanent discontinuation of Empliciti therapy and emergency treatment. 
Vrlo teške reakcije na infuziju (≥ 3. stupnja) mogu zahtijevati trajnu obustavu terapije lijekom Empliciti i hitno liječenje.
Infusion reaction Infusion reactions have been reported in patients receiving elotuzumab (see section 4.8). 
U bolesnika liječenih elotuzumabom prijavljene su reakcije na infuziju (vidjeti dio 4.8).
Below is a list of typical symptoms associated with infusion reactions: Fever Chills High blood pressure 
U nastavku slijedi popis tipičnih simptoma povezanih s reakcijama na infuziju:
Patients who were refractory to lenalidomide were excluded and 6% of patients had prior lenalidomide treatment. 
U ispitivanje nisu bili uključeni bolesnici refraktorni na lenalidomid, a 6% bolesnika je prethodno bilo liječeno lenalidomidom.
Very severe infusion reactions may require permanent discontinuation of Empliciti therapy and emergency treatment. 
Vrlo teške reakcije na infuziju mogu zahtijevati trajan prekid terapije lijekom Empliciti i hitno liječenje.
PFS ITT assessment per investigator was evaluated in several subgroups including age (< 65 versus ≥ 65), race, ISS stage, prior therapies, transplant, risk category, ECOG status, creatinine clearance, and cytogenic abnormalities. 
Ispitivač je ocjenjivao PFS u ITT populaciji u nekoliko podskupina, uključuju podskupine prema dobi (< 65 naspram ≥ 65 godina), rasi, stadiju prema ISS klasifikaciji, prethodnim terapijama, presađivanju, kategoriji rizika, ECOG statusu, klirensu kreatinina i citogenetskim abnormalnostima.
Elotuzumab is not expected to be excreted into human milk. 
Ne očekuje se izlučivanje elotuzumaba u majčino mlijeko.
Withdraw the necessary volume for the calculated dose from each vial, up to a maximum of 16 mL from 400 mg vial and 12 mL from 300 mg vial. 
Iz svake bočice izvucite potreban volumen za izračunatu dozu - najviše 16 ml iz bočice od 400 mg odnosno najviše 12 ml iz bočice od 300 mg.
The following side effects have been reported in clinical trials with elotuzumab: 
U kliničkim ispitivanjima elotuzumaba prijavljene su sljedeće nuspojave:
Improvements observed in PFS were consistent across subsets regardless of age (< 65 versus ≥ 65), risk status, presence or absence of cytogenetic categories del17p or t(4;14), ISS stage, number of prior therapies, prior immunomodulatory exposure, prior bortezomib exposure, relapsed or refractory status or renal function as shown in Table 9. 
Primijećena poboljšanja PFS-a bila su dosljedna u svim podskupinama, neovisno o dobi (< 65 naspram ≥ 65 godina), rizičnom statusu, prisutnosti ili odsutnosti citogenetskih kategorija del17p ili t(4;14), stadiju prema ISS klasifikaciji, broju prethodnih terapija, prethodnoj izloženosti imunomodulatorima, prethodnoj izloženosti bortezomibu, relapsnom ili refraktornom statusu ili funkciji bubrega, kao što je prikazano u Tablici 9.
If you miss a dose of Empliciti 
Ako ste propustili dozu lijeka Empliciti
The median age was 67 years (range 36 to 81); 62% of patients were older than 65 years; 57% of patients were male; whites comprised 77% of the study population, Asians 21%, and blacks 1%. 
Medijan dobi iznosio je 67 godina (raspon: 36 - 81); 62% bolesnika bilo je starije od 65 godina; 57% bolesnika bili su muškarci; bijelci su činili 77% ispitivane populacije, Azijci 21%, a crnci 1%.
Refer to the Summary of Product Characteristics for requirements regarding contraception due to presence and transmission in sperm and for additional detail. 
Pročitajte sažetak opisa svojstava lijeka za više informacija o zahtjevima koji se odnose na kontracepciju zbog prisutnosti lijeka u spermi i prijenosa spermom.
20 ml Type I glass vial, closed with a grey butyl stopper and sealed with aluminium crimp seal with a polypropylene flip off button, containing either 300 mg or 400 mg elotuzumab. 
Staklena bočica (staklo tipa I) od 20 ml, zatvorena sivim butilnim čepom i zapečaćena aluminijskim zaštitnim prstenom s polipropilenskom "flip off" kapicom, koja sadrži 300 mg ili 400 mg elotuzumaba.
From a microbiological point of view, the solution for infusion should be used immediately. 
S mikrobiološkog stanovišta, otopinu za infuziju treba odmah primijeniti.
The effect of renal impairment on the pharmacokinetics of elotuzumab was evaluated in patients with normal renal function (CrCl > 90 mL/min; N = 8), severe renal impairment not requiring dialysis (CrCl <30 mL/min; N = 9), or end-stage renal disease requiring dialysis (CrCl < 30 mL/min; N = 9). 
Učinak oštećenja funkcije bubrega na farmakokinetiku elotuzumaba ocjenjivao se u bolesnika s normalnom funkcijom bubrega (CrCl > 90 ml/min; N = 8), teškim oštećenjem funkcije bubrega koje nije zahtijevalo dijalizu (CrCl < 30 ml/min; N = 9) ili onih u terminalnoj fazi bubrežne bolesti kojima je bila potrebna dijaliza (CrCl < 30 ml/min; N = 9).
The other ingredients (excipients) are sucrose, sodium citrate (see section 2 “Empliciti contains sodium”), citric acid monohydrate, and polysorbate 80. 
Drugi sastojci (pomoćne tvari) su saharoza, natrijev citrat (pogledajte odlomak "Empliciti sadrži natrij" u dijelu 2.), citratna kiselina hidrat i polisorbat 80.
The rate of mild to moderate infusion reactions was > 50% in patients who were not premedicated. 
Stopa blagih do umjerenih reakcija na infuziju u bolesnika koji nisu primili premedikaciju bila je > 50%.
Prior therapies included stem cell transplant (55%), bortezomib (100%), lenalidomide (99%), cyclophosphamide (66%), melphalan (63%), carfilzomib (21%), ixazomib (6%), and daratumumab (3%). 
Prethodne terapije uključivale su presađivanje matičnih stanica (55%), bortezomib (100%), lenalidomid (99%), ciklofosfamid (66%), melfalan (63%), karfilzomib (21%), iksazomib (6%) i daratumumab (3%).
The most common adverse reactions (occurring in > 10% of patients) with elotuzumab treatment were infusion related reactions, diarrhoea, herpes zoster, nasopharyngitis, cough, pneumonia, upper respiratory tract infection, lymphopenia and weight decreased. 
Najčešće nuspojave (koje su se javile u > 10% bolesnika) kod liječenja elotuzumabom bile su reakcije na infuziju, proljev, herpes zoster, nazofaringitis, kašalj, pneumonija, infekcija gornjih dišnih putova, limfopenija i smanjenje tjelesne težine.
Treatment was administered in 4-week cycles (28-day cycle) until disease progression or unacceptable toxicity. 
Liječenje se primjenjivalo u 4-tjednim ciklusima (28-dnevni ciklusi) do progresije bolesti ili pojave neprihvatljive toksičnosti.
In clinical trials of patients with multiple myeloma, the incidence of all infections, including pneumonia, were higher in patients treated with Empliciti (see section 4.8). 
U kliničkim ispitivanjima provedenima u bolesnika s multiplim mijelomom, incidencija svih infekcija, uključujući pneumoniju, bila je viša u bolesnika liječenih lijekom Empliciti (vidjeti dio 4.8).
The rate of haematologic malignancies was the same between the two treatment arms. 
Stopa hematoloških zloćudnih bolesti bila je jednaka u obje liječene skupine.
The median number of treatment cycles was 9 for the E-Pd arm and 5 for the Pd arm. 
Medijan broja ciklusa liječenja iznosio je 9 u skupini koja je primala E-Pd te 5 u onoj koja je primala Pd.
Empliciti may be detected in the serum protein electrophoresis (SPEP) and serum immunofixation assays of myeloma patients and could interfere with correct response classification. 
Testovi elektroforeze serumskih proteina (engl. serum protein electrophoresis, SPEP) i imunofiksacije u serumu mogu u bolesnika s mijelomom detektirati lijek Empliciti, što može utjecati na točnu klasifikaciju odgovora.
For women taking Empliciti 
Za žene koje primaju Empliciti
Overall Response (ORR)c n (%) 
Ukupan odgovor (ORR)c n (%)
Sodium citrate Citric acid monohydrate Polysorbate 80 
Natrijev citrat Citratna kiselina hidrat Polisorbat 80
Empliciti will be given to you together with lenalidomide and dexamethasone or together with pomalidomide and dexamethasone. 
Empliciti ćete primati zajedno s lenalidomidom i deksametazonom ili zajedno s pomalidomidom i deksametazonom.
After reconstitution and dilution The reconstituted solution should be transferred from the vial into the infusion bag immediately. 
Nakon rekonstitucije i razrjeđivanja Rekonstituiranu otopinu treba odmah prenijeti iz bočice u infuzijsku vrećicu.
The median age was 66 years (range 37 to 91); 57% of patients were older than 65 years; 60% of patients were male; Whites comprised 84% of the study population, Asians 10%, and blacks 4%. 
Medijan dobi iznosio je 66 godina (raspon: 37 - 91); 57% bolesnika bilo je starije od 65 godina; 60% bolesnika bili su muškarci; bijelci su činili 84% ispitivane populacije, Azijati 10%, a crnci 4%.
Upon resolution to ≤ Grade 1, Empliciti should be restarted at 0.5 mL/min and may be gradually increased at a rate of 0.5 mL/min every 30 minutes as tolerated to the rate at which the infusion reaction occurred. 
Nakon što se reakcija ublaži do ≤ 1. stupnja, primjenu lijeka Empliciti treba ponovno započeti brzinom od 0,5 ml/min, koja se može postupno povećavati za 0,5 ml/min svakih 30 minuta sukladno podnošljivosti do brzine pri kojoj se pojavila reakcija na infuziju.
Table 10: CA204125 Efficacy results 
Tablica 10: Rezultati za djelotvornost u ispitivanju CA204125
When given in combination with pomalidomide and dexamethasone, Empliciti is given as follows: 
Kada se daje u kombinaciji s pomalidomidom i deksametazonom, Empliciti se primjenjuje na sljedeći način:
28-Day Cycles 3+ Day of Cycle 1 8 15 22 1 8 15 22 
Dan ciklusa 1 8 15 22 1 8 15 22
Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici bočice i kutiji iza oznake "Rok valjanosti".
Population PK analysis suggested that the following factors had no clinically important effect on the clearance of elotuzumab: age, gender, race, baseline LDH, albumin, renal impairment, mild hepatic impairment, and coadministration with lenalidomide/dexamethasone or pomalidomide/dexamethasone. 
Populacijska farmakokinetička analiza ukazala je na to da sljedeći faktori nemaju klinički značajnog učinka na klirens elotuzumaba: dob, spol, rasa, početni LDH, albumin, oštećenje funkcije bubrega, blago oštećenje funkcije jetre i istodobna primjena lenalidomida/deksametazona ili pomalidomida/deksametazona.
The administration of dexamethasone is as follows: 
Deksametazon se primjenjuje na sljedeći način:
Dexamethasone (mg) orally Day of Cycle 1 
Deksametazon (mg) peroralno Dan ciklusa 1.
For additional information concerning lenalidomide and dexamethasone, see the corresponding Summary of Product Characteristics. 
Za više informacija o lenalidomidu i deksametazonu pročitajte odgovarajuće sažetke opisa svojstava lijeka.
In study CA204004, the most common symptoms of an infusion reaction included fever, chills, and hypertension. 
Najčešći simptomi reakcije na infuziju u ispitivanju CA204004 uključivali su vrućicu, zimicu i hipertenziju.
The geometric mean total clearance of elotuzumab at 10 mg/kg (in combination with lenalidomide and dexamethasone) at steady state is 0.194 L/day (CV: 62.9%). 
Geometrijska srednja vrijednost ukupnog klirensa elotuzumaba pri dozi od 10 mg/kg (u kombinaciji s lenalidomidom i deksametazonom) u stanju dinamičke ravnoteže iznosi 0,194 L/danu (CV 62,9%)..
Elotuzumab exhibits nonlinear PK with decrease in clearance with increase in dose from 0.5-20 mg/kg. 
Elotuzumab pokazuje nelinearnu farmakokinetiku sa smanjenjem klirensa kod povećanja doze od 0,5 do 20 mg/kg.
Posology for administration with lenalidomide and dexamethasone The length of each treatment cycle is 28 days, see Table 1 for the dosing schedule. 
Doziranje kod primjene s lenalidomidom i deksametazonom Svaki ciklus liječenja traje 28 dana; vidjeti Tablicu 1 za raspored doziranja.
The incidence of infections, including pneumonia, was higher with Empliciti treatment than with control (see section 4.4). 
Incidencija infekcija, uključujući pneumoniju, bila je viša u bolesnika liječenih lijekom Empliciti nego u kontrolnoj skupini (vidjeti dio 4.4).
Prior therapies included: stem cell transplant (55%), bortezomib (70%) melphalan (65%), thalidomide (48%), and lenalidomide (6%). 
Prethodne terapije uključivale su: presađivanje matičnih stanica (55%), bortezomib (70%), melfalan (65%), talidomid (48%) i lenalidomid (6%).
Stratified log-rank test p-valuea 1-Year PFS rate (%) [95% CI] 2-Year PFS rate (%) [95% CI] 3-Year PFS rateb(%) [95% CI] Median PFS in months [95% CI] 
1-godišnja stopa PFS-a (%) [95% CI] 2-godišnja stopa PFS-a (%) [95% CI] 3-godišnja stopa PFS-ab
The rates of deep vein thromboses observed between treatment arms were similar for patients given prophylaxis with low molecular weight heparin (2.2% in both treatment arms), and for patients given vitamin K antagonists the rates were 0% for patients treated with E-Ld and 6.7% for patients treated with Ld. 
Stope duboke venske tromboze primijećene u liječenim skupinama bile su slične u bolesnika koji su primali profilaksu heparinom niske molekularne težine (2,2% u obje liječene skupine), dok je među bolesnicima koji su primali antagonistie vitamina K iznosila 0% u bolesnika koji su liječeni E-Ld-om te 6,7% u onih koji su liječeni Ld-om.
Posology for administration with pomalidomide and dexamethasone The length of each treatment cycle is 28 days, see Table 2 for the dosing schedule. 
Doziranje kod primjene s pomalidomidom i deksametazonom Svaki ciklus liječenja traje 28 dana; vidjeti Tablicu 2 za raspored doziranja.
The median number of treatment cycles was 19 for the Empliciti arm and 14 for the comparator arm. 
Medijan broja ciklusa liječenja iznosio je 19 u skupini koja je primala Empliciti te 14 u usporednoj skupini.
No clinically important differences in the pharmacokinetics of elotuzumab were found between patients with severe renal impairment (with and without dialysis) and patients with normal renal function (see section 4.2). 
Nisu primijećene klinički značajne razlike u farmakokinetici elotuzumaba između bolesnika s teškim oštećenjem funkcije bubrega (neovisno o dijalizi) i onih s normalnom funkcijom bubrega (vidjeti dio 4.2).
In cycles 3 and beyond, once every 2 weeks on days 1 and 15. 
U 3. i svim sljedećim ciklusima jedanput svaka 2 tjedna, 1. i 15. dana.
The International Staging System (ISS) Stage was I in 43%, II in 32% and III in 21% of patients. 
International Staging System, ISS) bio je I u 43% bolesnika, II u 32% bolesnika te III u 21% bolesnika.
Of 390 patients across four clinical studies who were treated with Empliciti and evaluable for the presence of anti-product antibodies, 72 patients (18.5%) tested positive for treatment-emergent anti-product antibodies by an electrochemiluminescent (ECL) assay. 
Od 390 bolesnika iz četiri klinička ispitivanja koji su liječeni lijekom Empliciti i u kojih se mogla odrediti prisutnost protutijela na lijek, 72 bolesnika (18,5%) imala su pozitivan nalaz elektrokemiluminiscencijskog testa na protutijela na lijek nastala tijekom liječenja.
One patient was reported to be overdosed with 23.3 mg/kg of elotuzumab in combination with lenalidomide and dexamethasone. 
U jednog je bolesnika prijavljeno predoziranje dozom elotuzumaba od 23,3 mg/kg u kombinaciji s lenalidomidom i deksametazonom.
After reconstitution, each mL of concentrate contains 25 mg elotuzumab. 
Nakon rekonstitucije, jedan ml koncentrata sadrži 25 mg elotuzumaba.
If a ≥ Grade 2 infusion reaction occurs during Empliciti administration, the infusion must be interrupted. 
Ako se tijekom primjene lijeka Empliciti pojavi reakcija na infuziju ≥ 2. stupnja, infuzija se mora privremeno prekinuti.
Treatment was administered in 4-week cycles until disease progression or unacceptable toxicity. 
Liječenje se primjenjivalo u 4-tjednim ciklusima do progresije bolesti ili pojave neprihvatljive toksičnosti.
Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1). 
Empliciti je indiciran u kombinaciji s lenalidomidom i deksametazonom za liječenje multiplog mijeloma u odraslih bolesnika koji su prethodno primili najmanje jednu terapiju (vidjeti dijelove 4.2 i 5.1).
On days that Empliciti is not administered but a dose of dexamethasone is scheduled (Days 8 and 22 of cycle 3 and all subsequent cycles), dexamethasone should be given 40 mg orally. 
Onih dana kada se Empliciti ne primjenjuje, a predviđena je primjena doze deksametazona (8. i 22. dan 3. i svih sljedećih ciklusa), deksametazon treba davati peroralno u dozi od 40 mg.
The safety data of elotuzumab have been assessed from a total of 682 patients with multiple myeloma treated with elotuzumab in combination with lenalidomide and dexamethasone (451 patients), bortezomib and dexamethasone (103 patients) or pomalidomide and dexamethasone (128 patients) pooled across 8 clinical trials. 
Ocijenjeni su objedinjeni podaci o sigurnosti elotuzumaba prikupljeni u ukupno 682 bolesnika s multiplim mijelomom liječena elotuzumabom u kombinaciji s lenalidomidom i deksametazonom (451 bolesnik), bortezomibom i deksametazonom (103 bolesnika) ili pomalidomidom i deksametazonom (128 bolesnika) u 8 kliničkih ispitivanja.
PVC infusion sets polyethersulfone and nylon in-line filters with pore sizes of 0.2 μm to 1.2 μm. 
Infuzija lijeka Empliciti kompatibilna je sa: spremnicima od PVC-a i poliolefina infuzijskim setovima od PVC-a polietersulfonskim i najlonskim in-line filtrima s veličinom pora od 0,2 µm do 1,2 µm.
Elotuzumab also targets SLAMF7 on myeloma cells and through interactions with Fc receptors on specific immune cells, promotes the killing of myeloma cells through NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and macrophage-mediated antibody-dependant cellular phagocytosis (ADCP). 
Elotuzumab također ciljano djeluje na SLAMF7 na stanicama mijeloma te interakcijama s Fc receptorima na specifičnim imunosnim stanicama pridonosi uništavanju stanica mijeloma putem stanične citotoksičnosti ovisne o protutijelima (engl. antibody-dependent cellular cytotoxicity, ADCC) posredovane NK stanicama i stanične fagocitoze ovisne o protutijelima (engl. antibody-dependent cellular phagocytosis, ADCP) posredovane makrofagima.
When given in combination with lenalidomide and dexamethasone, Empliciti is given as follows: 
Kada se daje u kombinaciji s lenalidomidom i deksametazonom, Empliciti se primjenjuje na sljedeći način:
Empliciti, as a humanised monoclonal antibody, is not expected to be metabolised by cytochrome P450 (CYP) enzymes or other drug metabolising enzymes, inhibition or induction of these enzymes by co-administered medicinal products is not anticipated to affect the pharmacokinetics of Empliciti. 
Budući da je Empliciti humanizirano monoklonsko protutijelo, ne očekuje se da će ga metabolizirati enzimi citokroma P450 (CYP) niti drugi enzimi koji metaboliziraju lijekove.
A total of 117 patients were randomised in a 1:1 ratio to receive treatment: 60 to elotuzumab in combination with pomalidomide and dexamethasone (E-Pd) and 57 to pomalidomide and dexamethasone (Pd). 
Ukupno je 117 bolesnika bilo randomizirano za liječenje (u omjeru 1:1): 60 za primanje elotuzumaba u kombinaciji s pomalidomidom i deksametazonom (E-Pd) i 57 za primanje pomalidomida i deksametazona (Pd).
HR (95% CI): 0.54 (0.34, 0.86) p-value: 0.0078 
HR (95% CI): 0,54 (0,34; 0,86) p-vrijednost: 0,0078
SLAMF7 is found in large amounts on the surface of multiple myeloma cells and on certain cells of your immune system (natural killer cells). 
SLAMF7 se u velikim količinama nalazi na površini stanica multiplog mijeloma te na određenim stanicama imunosnog sustava (NK stanicama).
The total elotuzumab dose in mg equals the patient's weight in kg multiplied by the elotuzumab dose (10 or 20 mg/kg, see section 4.2). 
Ukupna doza elotuzumaba u mg jednaka je bolesnikovoj tjelesnoj težini u kg pomnoženoj s dozom elotuzumaba (10 ili 20 mg/kg, vidjeti dio 4.2).